相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid
Philip G. Drennan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers
Richard J. Everts et al.
JOURNAL OF INFECTION (2021)
Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers
Richard J. Everts et al.
JOURNAL OF INFECTION (2020)
From 'OPAT' to 'COpAT': implications of the OVIVA study for ambulatory management of bone and joint infection
R. A. Seaton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study
Gunilla Skoog Stahlgren et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers
Timothy M. Rawson et al.
LANCET DIGITAL HEALTH (2019)
Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe
Mike Sharland et al.
LANCET INFECTIOUS DISEASES (2018)
Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis A Meta-analysis of Individual Patient Data from Randomized Trials
Jason A. Roberts et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists
M. Gilchrist et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans
Kazuya Maeda et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Therapeutic drug monitoring of antimicrobials
Jason A. Roberts et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The History and Future of Probenecid
Nathan Robbins et al.
CARDIOVASCULAR TOXICOLOGY (2012)
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
Fekade Bruck Sime et al.
ANNALS OF INTENSIVE CARE (2012)
Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration
I. Bilgrami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?
Jason A. Roberts et al.
CURRENT OPINION IN CRITICAL CARE (2008)
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa
VH Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults
ML Grayson et al.
CLINICAL INFECTIOUS DISEASES (2002)
分享论文
